LOTUS PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 301 TWD | +4.88% |
|
+4.70% | +10.66% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,958 | 19,628 | 25,569 | 64,462 | 71,935 | 79,605 | - |
| Enterprise Value (EV) 1 | 33,440 | 23,614 | 29,450 | 71,231 | 71,935 | 86,491 | 82,250 |
| P/E ratio | 42 x | 19 x | 17.8 x | 21.2 x | 17.3 x | 16.2 x | 12.7 x |
| Yield | - | - | 1.98% | 1.41% | - | 1.78% | 2.49% |
| Capitalization / Revenue | 3.05 x | 1.83 x | 2.02 x | 4.41 x | 4.24 x | 4.22 x | 3.8 x |
| EV / Revenue | 3.64 x | 2.2 x | 2.33 x | 4.87 x | 4.24 x | 4.59 x | 3.93 x |
| EV / EBITDA | 19.7 x | 10.2 x | 9.64 x | 14.1 x | 11.8 x | 11.8 x | 10.2 x |
| EV / FCF | -1,095 x | 15.4 x | -65 x | 22.7 x | - | 23.2 x | 16.4 x |
| FCF Yield | -0.09% | 6.5% | -1.54% | 4.41% | - | 4.31% | 6.09% |
| Price to Book | 3.61 x | 2.24 x | 2.31 x | 4.62 x | - | 3.92 x | 2.91 x |
| Nbr of stocks (in thousands) | 243,114 | 245,354 | 262,246 | 262,041 | 264,468 | 264,468 | - |
| Reference price 2 | 115.0 | 80.00 | 97.50 | 246.0 | 272.0 | 301.0 | 301.0 |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,175 | 10,729 | 12,649 | 14,633 | 16,958 | 18,861 | 20,954 |
| EBITDA 1 | 1,700 | 2,322 | 3,054 | 5,048 | 6,114 | 7,352 | 8,040 |
| EBIT 1 | 1,113 | 1,613 | 2,295 | 4,111 | 4,903 | 6,424 | 7,150 |
| Operating Margin | 12.13% | 15.03% | 18.14% | 28.1% | 28.91% | 34.06% | 34.12% |
| Earnings before Tax (EBT) 1 | 876.4 | 1,304 | 1,870 | 3,940 | 5,103 | 6,182 | 7,889 |
| Net income 1 | 662.8 | 1,030 | 1,403 | 3,021 | 4,106 | 4,822 | 6,170 |
| Net margin | 7.22% | 9.6% | 11.09% | 20.64% | 24.21% | 25.57% | 29.45% |
| EPS 2 | 2.740 | 4.220 | 5.470 | 11.59 | 15.72 | 18.57 | 23.70 |
| Free Cash Flow 1 | -30.53 | 1,535 | -453.1 | 3,142 | - | 3,726 | 5,005 |
| FCF margin | -0.33% | 14.31% | -3.58% | 21.47% | - | 19.75% | 23.89% |
| FCF Conversion (EBITDA) | - | 66.09% | - | 62.25% | - | 50.68% | 62.25% |
| FCF Conversion (Net income) | - | 149.07% | - | 104.02% | - | 77.26% | 81.11% |
| Dividend per Share 2 | - | - | 1.930 | 3.460 | - | 5.365 | 7.505 |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,803 | 3,161 | 2,910 | 5,389 | 3,172 | 4,524 | 4,442 | 4,573 | 3,419 | 4,198 | 5,056 | 5,260 | 4,325 | 4,951 | 4,911 |
| EBITDA 1 | 586.7 | 832.5 | 730.4 | 2,881 | - | 1,964 | 1,908 | 1,775 | 469.5 | 1,572 | 1,979 | 2,126 | 982 | - | - |
| EBIT 1 | 392.5 | 623.5 | 490.2 | 2,641 | 356.3 | 1,664 | 1,614 | 1,482 | 143.4 | 1,256 | 1,943 | 2,062 | 1,043 | 1,875 | 1,836 |
| Operating Margin | 14% | 19.72% | 16.84% | 49.01% | 11.24% | 36.78% | 36.33% | 32.41% | 4.19% | 29.91% | 38.44% | 39.21% | 24.12% | 37.87% | 37.39% |
| Earnings before Tax (EBT) 1 | 320.2 | 588.6 | 426.8 | 2,630 | 294.8 | 1,505 | 1,524 | 1,566 | 508.2 | 1,306 | 1,820 | 1,986 | 947 | 1,792 | 1,755 |
| Net income 1 | 251.3 | 446.1 | 327.7 | 2,079 | 167.6 | 1,194 | 1,266 | 1,246 | 400 | 1,036 | 1,419 | 1,550 | 730.5 | 1,390 | 1,354 |
| Net margin | 8.96% | 14.11% | 11.26% | 38.58% | 5.28% | 26.39% | 28.5% | 27.24% | 11.7% | 24.68% | 28.07% | 29.47% | 16.89% | 28.07% | 27.56% |
| EPS 2 | 0.9500 | 1.710 | 1.250 | 7.930 | 0.6300 | 4.550 | 4.840 | 4.760 | 1.530 | 3.940 | 5.390 | 5.880 | 2.770 | 5.280 | 5.140 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/03/22 | 13/05/22 | 11/08/22 | 10/11/22 | 14/03/23 | 15/05/23 | 11/08/23 | 10/11/23 | 15/03/24 | 11/05/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5,482 | 3,986 | 3,881 | 6,769 | - | 6,886 | 2,645 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.225 x | 1.716 x | 1.271 x | 1.341 x | - | 0.9366 x | 0.329 x |
| Free Cash Flow 1 | -30.5 | 1,535 | -453 | 3,142 | - | 3,726 | 5,005 |
| ROE (net income / shareholders' equity) | 8.86% | 12.5% | 14.2% | 24.2% | - | 22.8% | 24.4% |
| ROA (Net income/ Total Assets) | 4.05% | 5.43% | 6.85% | 11.9% | - | 12.6% | 13.8% |
| Assets 1 | 16,386 | 18,974 | 20,482 | 25,374 | - | 38,272 | 44,659 |
| Book Value Per Share 2 | 31.80 | 35.60 | 42.10 | 53.20 | - | 76.90 | 103.0 |
| Cash Flow per Share 2 | 1.250 | 7.990 | 0.4700 | 14.30 | - | 21.40 | 28.20 |
| Capex 1 | 333 | 414 | 573 | 577 | - | 395 | 489 |
| Capex / Sales | 3.63% | 3.86% | 4.53% | 3.94% | - | 2.09% | 2.33% |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
301
TWD
Average target price
393.2
TWD
Spread / Average Target
+30.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.66% | 2.47B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 1795 Stock
- Financials Lotus Pharmaceutical Co., Ltd.
